Research brief • May 25, 2026

Retatrutide “GLP-3” + MOTS-c: PubMed vs Trial Registry Checks

The linked PDR video topic is still retatrutide — often called “GLP-3” in social posts — plus MOTS-c. Today's reader version focuses on one simple research habit: check whether a claim is supported by a peer-reviewed PubMed record, an active ClinicalTrials.gov listing, a mechanism paper, or only a viral shorthand.

Educational disclaimer: This article is for research literacy only and is not medical advice. It does not provide dosing, protocols, reconstitution instructions, treatment plans, sourcing instructions, or recommendations to buy or use any compound. Affiliate disclosure: I may earn a commission from links on this site, at no extra cost to you.

Free research kit

Use the same source-checking workflow on any peptide trend.

Get plain-English claim filters, PubMed prompts, COA notes, and research-literacy links without protocols or medical advice.

Get the free research kit

Start by translating the nickname

“GLP-3” is an online nickname, not the best scientific search term. Retatrutide is commonly indexed as retatrutide, LY3437943, or a triple-hormone-receptor agonist involving GIP, GLP-1, and glucagon receptor signaling. That difference matters because PubMed and ClinicalTrials.gov respond better to the formal compound names than to social-media shorthand.

A clean source check starts with the real search term, then asks what kind of evidence appears. A published Phase 2 paper, an active Phase 3 registry listing, a company update, and a creator caption all deserve different confidence language.

PubMed answers one question; ClinicalTrials.gov answers another

PubMed helps readers find peer-reviewed records and abstracts. For retatrutide, that includes human clinical publications such as the 2023 New England Journal of Medicine Phase 2 obesity trial, a 2023 Lancet Phase 2 type 2 diabetes study, a 2024 Nature Medicine Phase 2a study in metabolic dysfunction-associated steatotic liver disease, and a 2026 lipid/metabolite profile paper.

ClinicalTrials.gov is different. It can show whether a study exists, whether it is recruiting, active, completed, or otherwise listed, and what the official title or endpoint structure looks like. It does not automatically mean a peer-reviewed outcome paper is available. The registry is useful, but it should not be read as proof of a finished result unless results or linked publications support that interpretation.

Retatrutide has human-trial records; the claim still needs boundaries

Retatrutide is the stronger evidence-side topic in this pair because it has identifiable human trial publications and multiple trial registry records. The careful wording is not “this guarantees an outcome.” The careful wording is “researchers have evaluated retatrutide in human metabolic studies with defined endpoints, populations, durations, and safety reporting.”

When a post reduces the topic to a dramatic “GLP-3” label, look for what was actually measured. Was the claim tied to body-weight endpoints, glycemic endpoints, liver-fat or metabolic-dysfunction endpoints, lipid and metabolite profiles, adverse events, discontinuations, or an ongoing trial design? That is where research literacy starts.

MOTS-c is more mechanism-forward, with registry signals to watch

MOTS-c is usually discussed as a mitochondrial-derived peptide connected to metabolic homeostasis, stress-response pathways, exercise biology, and aging-related mechanisms. That makes it an important research-literacy topic, but mechanism language is not the same as clinical proof.

The fresh registry check found a MOTS-c listing described as a recruiting study for improving insulin sensitivity in adults with prediabetes and overweight/obesity. That is worth watching as a research signal, but it should not be converted into usage instructions, treatment advice, or outcome promises. The best public-facing phrasing is still cautious: researchers are evaluating questions around MOTS-c, and the evidence base remains more mechanism-forward than retatrutide's human-trial publication record.

The five video angles as a blog checklist

1. Name the formal term

Search retatrutide or LY3437943 instead of relying only on “GLP-3.” Search MOTS-c with the hyphen and without it when checking databases.

2. Identify the evidence tier

Separate peer-reviewed papers, trial registries, mechanism reviews, company materials, and social posts before judging a claim.

3. Read endpoints, not vibes

Look for population, duration, comparator, endpoints, safety reporting, and discontinuation details instead of headline-only interpretation.

4. Keep MOTS-c language cautious

Mechanism and pathway interest should be framed as “studied” or “being evaluated,” not as a practical protocol or guaranteed result.

5. Avoid the advice trap

Research literacy can explain evidence quality without telling readers to buy, dose, inject, combine, or use a compound.

A simple “PubMed vs registry” reading rule

If a claim points to PubMed, ask whether the paper is a human trial, review, preclinical model, data-mining analysis, or commentary. If a claim points to ClinicalTrials.gov, ask whether the study is completed, recruiting, active but not recruiting, or only registered without published results. Both tools are useful, but they answer different questions.

For retatrutide, PubMed and registry records can be used together to understand the study landscape. For MOTS-c, a mix of mechanism papers, reviews, and registry entries should be interpreted with extra care. That difference is the core takeaway from the video topic.

Research-only supplier note

If readers compare research suppliers, the education-first questions are documentation, posted testing, lot-specific COAs, independent verification, label clarity, and legal or regulatory fit. This is not buying advice and it is not a recommendation to purchase, dose, inject, combine, or use any compound.

View research supplier

Affiliate disclosure: I may earn a commission. Educational content only — not medical advice.

Compare research supplier transparencyReview posted testing, documentation, disclosures, and claim boundaries →Use the COA checklistCheck lot numbers, methods, purity, and identity signals before trusting claims →Learn ClinicalTrials.gov basicsRead registry status, phases, endpoints, and result limits more carefully →

Sources checked

Peptide Daily Report

Want the next source-first peptide brief?

Join the education-first list for PubMed checks, registry-reading notes, and new PDR article drops.